Abstracts tagged "psoriasis and psoriatic arthritis"

Abstract Number: 663 • 2018 ACR/ARHP Annual Meeting
Relative Contributions of Improvements in the Psoriasis Area and Severity Index (PASI) and Disease Activity Index for Psoriatic Arthritis (DAPSA) to Improvements in Quality of Life and Function in Patients with Psoriatic Arthritis
Alexis Ogdie¹, Prashanth Sunkureddi², Baojin Zhu³, Aubrey Spraberry⁴, William Malatestinic⁴, Yan Dong⁴ and David Shrom³, ¹University of Pennsylvania, Philadelphia, PA, ²Rheumatology, Clear Lake Rheumatology Center, Nassau Bay, TX, ³LRL, Eli Lilly and Company, Indianapolis, IN, ⁴Eli Lilly and Company, Indianapolis, IN
Background/Purpose: Psoriatic arthritis (PsA) is a heterogeneous inflammatory condition characterized by the clinical domains of arthritis, enthesitis, dactylitis, spondylitis, and psoriasis. While it is known…
Abstract Number: 683 • 2018 ACR/ARHP Annual Meeting
Spanish Validation of the Gepard Questionnaire for the Detection of Psoriatic Arthritis in Argentinean Patients with Psoriasis
María Victoria Martire¹, María Paula Girard Bosch¹, Santiago Scarafia², Vanesa Laura Cosentino³, María Janina Tapia⁴, Eduardo Kerzberg³, Natalia Estrella⁵, Cristian Troitiño⁶, Josefina Marin⁷, Fernando Andres Sommerfleck⁸, Hernán Maldonado Ficco⁹, Erika Catay¹⁰, Mariana Benegas¹¹ and Enrique R Soriano¹², ¹Rheumatology, Instituto Médico Platense, La Plata, Argentina, ²Rheumatology, Instituto de Asistencia Reumatológica Integral, Buenos Aires, Argentina, ³Ramos Mejía Hospital, Buenos Aires, Argentina, ⁴Reumatology, Hospital General de Agudos José María Ramos Mejía, Buenos Aires, Argentina, ⁵Consultorio Privado, Buenos Aires, Argentina, ⁶Reumatologia, Hospital Bernardino Rivadavia, CAPITAL FEDERAL, Argentina, ⁷Hospital Italiano de Buenos Aires, Buenos Aires, Argentina, ⁸Rheumatology, Instituto de Rehabilitación Psicofísica, Buenos Aires, Argentina, ⁹section of Rheumatology, Clinica Regional Del Sud, Rio Cuarto, Argentina, ¹⁰Consultorios Moreno, Formosa, Argentina, ¹¹Rheumatology Section, Sanatorio Dr. Julio Méndez, Buenos Aires, Argentina, ¹²Rheumatology Unit, Internal Medicine Service. Hospital Italiano Buenos Aires. Argentina, Buenos Aires, Argentina
Background/Purpose: Psoriatic Arthritis (PSA) is preceded by the presence of cutaneous psoriasis (PS) in approximately 80% of the cases. We consider relevant to have tools…
Abstract Number: 628 • 2017 ACR/ARHP Annual Meeting
Integrated Efficacy Results from Two Phase 3 Trials of Ixekizumab for the Treatment of Psoriatic Arthritis
Bernard Combe¹, Peter Nash², David Adams³, Lisa Kerr³ and Olivier Benichou³, ¹Rheumatology, CHU Lapeyronie and Montpellier University, Montpellier, France, ²University of Queensland, Brisbane, Australia, ³Eli Lilly and Company, Indianapolis, IN
Background/Purpose: Ixekizumab (IXE) is a high-affinity monoclonal antibody that selectively targets interleukin-17A. Here, we present integrated efficacy data at Week 24 from two phase 3…
Abstract Number: 647 • 2017 ACR/ARHP Annual Meeting
Gene Expression in Cellular Subsets in Psoriatic Disease
Anastasiya Muntyanu¹, Fatima Abji², Remy Pollock¹, Vinod Chandran² and Dafna D Gladman², ¹University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ²Rheumatology, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada
Background/Purpose: Psoriatic arthritis is an inflammatory musculoskeletal disease which develops in 30% of patients with psoriasis. Our previous peripheral blood microarray study identified CXCL10, NOTCH2NL,…
Abstract Number: 994 • 2017 ACR/ARHP Annual Meeting
Increasing Population Burden of Psoriatic Disease in Ontario, Canada – a Longitudinal Cohort Study
Lihi Eder^1,2, Jessica Widdifield³, Cheryl F. Rosen⁴, Dafna D Gladman^2,5, Raed Alhusayen⁶, Michael Paterson⁷, Stephanie Cheng⁷, Shirin Jabbari⁷, Willemina Campbell⁸, Sasha Bernatsky⁹ and Karen Tu⁷, ¹Women's College Research Institute, Women's College Hospital, Toronto, ON, Canada, ²Medicine, University of Toronto, Toronto, ON, Canada, ³University Health Network, Toronto, ON, Canada, ⁴Dermatology, Toronto Western Hospital, University of Toronto, Toronto, ON, Canada, ⁵Rheumatology, University Health Network, Toronto, ON, Canada, ⁶Sunnybrook Research Institute, Sunnybrook Health Sciences Centre, Toronto, ON, Canada, ⁷Institute for Clinical Evaluative Sciences, Toronto, ON, Canada, ⁸Rheumatology, Toronto Western Hospital, Toronto, ON, Canada, ⁹Divisions of Rheumatology and Clinical Epidemiology, Research Institute of the McGill University Health Centre, Montreal, QC, Canada
Background/Purpose: There is limited information on the epidemiology of psoriasis and psoriatic arthritis (PsA) in North America. The aims of this study were to estimate…
Abstract Number: 995 • 2017 ACR/ARHP Annual Meeting
The Epidemiology of Psoriatic Arthritis in Israel – a Population-Based Study
Lihi Eder^1,2, Arnon Dov Cohen³, Ilan Feldhamer⁴, Sari Greenberg-Dotan⁴, Eraz Batat⁴ and Devy Zisman⁵, ¹Women's College Research Institute, Women's College Hospital, Toronto, ON, Canada, ²Medicine, University of Toronto, Toronto, ON, Canada, ³3Chief Physician’s Office, Central Headquarters, Clalit Health Services, Tel Aviv, Israel, ⁴Chief Physician’s Office, Central Headquarters, Clalit Health Services, Tel Aviv, Israel, ⁵The Ruth and Bruce Rappaport Faculty of Medicine, Technion, Haifa, Israel
Background/Purpose: There is limited information on the epidemiology of Psoriatic Arthritis (PsA) in general and in Middle Eastern populations in particular. The aims of this…
Abstract Number: 996 • 2017 ACR/ARHP Annual Meeting
Accuracy of Canadian Administrative Health Data in Identifying Patients with Psoriasis and Psoriatic Arthritis Using Primary Care Medical Records As the Reference Standard
Lihi Eder^1,2, Jessica Widdifield³, Cheryl F. Rosen⁴, Dafna D Gladman², Raed Alhusayen⁵, Michael Paterson⁶, Stephanie Cheng⁶, Shirin Jabbari⁶, Willemina Campbell⁷, Sasha Bernatsky⁸ and Karen Tu⁶, ¹Women's College Research Institute, Women's College Hospital, Toronto, ON, Canada, ²Medicine, University of Toronto, Toronto, ON, Canada, ³University Health Network, Toronto, ON, Canada, ⁴Dermatology, Toronto Western Hospital, University of Toronto, Toronto, ON, Canada, ⁵Sunnybrook Research Institute, Sunnybrook Health Sciences Centre, Toronto, ON, Canada, ⁶Institute for Clinical Evaluative Sciences, Toronto, ON, Canada, ⁷Rheumatology, Toronto Western Hospital, Toronto, ON, Canada, ⁸Divisions of Rheumatology and Clinical Epidemiology, Research Institute of the McGill University Health Centre, Montreal, QC, Canada
Background/Purpose: We assessed the accuracy of algorithms to identify patients with psoriasis and psoriatic arthritis (PsA) in administrative health data in a validation set derived…
Abstract Number: 1558 • 2017 ACR/ARHP Annual Meeting
Changes in Blood Pressure with TNF Inhibitors for Psoriatic Arthritis
Birju D. Bhatt¹, J. Lynn Palmer², Jeffrey R. Curtis³, Sathya Velkuru⁴ and Joel Kremer⁵, ¹Medicine, div-of Rheumatology, Albany Medical College, Albany, NY, ²Corrona Research Foundation, Albany, NY, ³Rheumatology & Immunology, University of Alabama at Birmingham, Birmingham, AL, ⁴Medicine, Albany Medical College, Albany, NY, ⁵Albany Medical College and the Center for Rheumatology, Albany, NY
Background/Purpose: Psoriasis is a complex disorder with cutaneous and rheumatological manifestations affecting 2-3% of the population of the Western world. The prevalence of hypertension (HTN)…
Abstract Number: 1571 • 2017 ACR/ARHP Annual Meeting
Bimekizumab Dual Inhibition of IL-17A and IL-17F Provides Evidence of IL-17F Contribution to Chronic Inflammation in Disease-Relevant Cells
Ash Maroof¹, Remi Okoye¹, Tim Smallie¹, Dominique Baeten^2,3, Sophie Archer¹, Catherine Simpson¹, Meryn Griffiths¹ and Stevan Shaw¹, ¹UCB Pharma, Slough, United Kingdom, ²UCB Pharma, Brussels, Belgium, ³University of Amsterdam, Amsterdam, Netherlands
Background/Purpose: IL-17A and IL-17F share structural homology and have similar biologic function.1 Although the contribution of IL-17A to immune-mediated inflammatory diseases has been widely reported,1,2…
Abstract Number: 1577 • 2017 ACR/ARHP Annual Meeting
Deciphering the Role of the Tissue Microenvironment in Shaping the Immune Landscape in Psoriatic Arthritis
Jin Hui Sherlynn Chan¹, Ying Ying Leung², Warren Fong², Yi Wei Yeo², Bhairav Paleja¹, Liyun Lai¹, Suzan Saidin¹, Camillus Chua¹, Sharifah Nur Hazirah¹, Su Li Poh¹, Andrea Hsiu Ling Low² and Salvatore Albani^1,3, ¹SingHealth Translational Immunology and Inflammation Centre (STIIC), Duke-NUS Medical School, Singapore, Singapore, ²Singapore General Hospital, Singapore, Singapore, ³KK Women's and Children's Hospital, Singapore, Singapore
Background/Purpose: Psoriatic arthritis (PsA) occurs in a third of patients with psoriasis (Ps) and up to 30% of patients with PsA do not have an…
Abstract Number: 1912 • 2017 ACR/ARHP Annual Meeting
Broad Immunophenotyping Results: CCR10 Expressing CD8 T Cells Distinguish Psoriatic Arthritis from Psoriasis Limited to Skin Involvement
Emmerik F.A. Leijten^1,2, Tessa S. van Kempen^1,2, Michel A.M. Olde Nordkamp^1,2, Fleurieke H. Verhagen^2,3, Sanne Hiddingh^2,3, Jonas J.W. Kuiper^2,3, Marianne L. Boes^2,4 and Timothy R.D.J. Radstake^1,2, ¹Department of Rheumatology & Clinical Immunology, University Medical Center Utrecht, Utrecht, Netherlands, ²Laboratory of Translational Immunology, University Medical Center Utrecht, Utrecht, Netherlands, ³Ophthalmology, University Medical Center Utrecht, Utrecht, Netherlands, ⁴Department of Pediatrics, University Medical Center Utrecht, Utrecht, Netherlands
Background/Purpose: Studies that compare the immune cell phenotype or function from patients with psoriatic arthritis (PsA) to patients with psoriasis limited to cutaneous involvement (Pso)…
Abstract Number: 2522 • 2017 ACR/ARHP Annual Meeting
Metabolic Syndrome, NAFLD and LIVER Stiffness in Psoriatic Arthritis and Psoriasis Patients: A CROSS-Sectional Study
Augusta Ortolan¹, Mariagrazia Lorenzin¹, Giulia Tadiotto¹, Francesca Oliviero¹, Ariela Hoxha¹, Marta Favero², Stefano Piaserico³, Leonardo Punzi¹ and Roberta Ramonda¹, ¹Rheumatology Unit, Department of Medicine DIMED, University of Padova, Padova, Italy, ²Rheumatology Unit,Department of Medicine DIMED, University of Padova, Padova, Italy, ³Dermatology Clinic, University of Padova, Padova, Italy
Background/Purpose: Metabolic syndrome (MetS) and non-alcoholic fatty liver disease (NAFLD, potentially evolving into liver fibrosis-LF), are more frequent in patient with psoriasis (PsO) with respect…
Abstract Number: 2539 • 2017 ACR/ARHP Annual Meeting
The Contribution of Skin and Joint Improvements to the Health-Related Quality of Life of Patients with Active Psoriatic Arthritis
Arthur Kavanaugh¹, Alice B Gottlieb², Akimichi Morita³, Joseph Merola⁴, Julie Birt⁵, Chen-Yen Lin⁵, Catherine Shuler⁵ and Diamant Thaçi⁶, ¹Medicine, University of California, San Diego, La Jolla, CA, ²Department of Dermatology, New York Medical College, Vallhalla, NY, ³Dept of Geriatric & Environmental Dermatology, Nagoya City Univ Medical School, Nagoya, Japan, ⁴Clinical Unit for Research Innovation & Trials, Harvard Medical School, Boston, MA, ⁵Eli Lilly and Company, Indianapolis, IN, ⁶Comprehensive Center for Inflammation Medicine, University Hospital Schleswig-Holstein Campus Luebeck, Ratzeburger Allee, Germany
Background/Purpose: Psoriatic arthritis (PsA) is a chronic immune-mediated inflammatory disease affecting peripheral and axial joints. For patients with active psoriasis, the added burden of skin…
Abstract Number: 2549 • 2017 ACR/ARHP Annual Meeting
Achievement of Minimal Disease Activity Is Associated with Improvements in Health-Related Quality of Life and Productivity in Psoriatic Arthritis Patients
Laura C Coates¹, Ana-Maria Orbai², Julie Birt³, Lisa Kerr³, Olivier Benichou³ and Philip S. Helliwell⁴, ¹University of Oxford, Leeds, Great Britain, ²Johns Hopkins University School of Medicine, Baltimore, MD, ³Eli Lilly and Company, Indianapolis, IN, ⁴School of Medicine, University of Leeds, Leeds, United Kingdom
Background/Purpose: Treatment goals in psoriatic arthritis (PsA) are moving toward attainment of absolute therapeutic thresholds rather than relative improvement. Minimal disease activity (MDA), a composite…
Abstract Number: 2879 • 2017 ACR/ARHP Annual Meeting
Switching from Adalimumab to Chs-1420: A Randomized, Double-Blind Global Clinical Trial in Patients with Psoriasis and Psoriatic Arthritis
Jennifer Hodge, Hong Tang, Paula O'Connor and Barbara Finck, Coherus BioSciences, Inc., Redwood City, CA
Background/Purpose: CHS-1420 is a proposed biosimilar to adalimumab. A phase 3, randomized, double-blind, multicenter study evaluated the equivalence of CHS-1420 to adalimumab in patients with…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].